On April 3, 2024 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET (Press release, CRISPR Therapeutics, APR 3, 2024, View Source [SID1234641736]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

On April 3, 2024 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported the signing of a Clinical Supply Agreement with NorthStar Medical Radioisotopes, LLC (NorthStar) for the production of 67Cu-SAR-bisPSMA drug product for Phase I/II and Phase III trials (Press release, Clarity Pharmaceuticals, APR 3, 2024, View Source [SID1234641735]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, "This important step is yet another differentiating factor that helps Clarity clearly stand out from the rest of the radiopharmaceutical market, making it possible to have therapeutic isotope supply and product manufacture at the same site. We have seen in the past the logistical challenges associated with the separation of radioisotope and final drug product manufacturing with lutetium-177 (Lu-177 or 177Lu) based therapies as it causes delays and inefficiencies, ultimately affecting care for oncology patients waiting for their treatments. Alpha-emitter therapies, such as those involving actinium-225 (Ac-225 or 225Ac) and lead-212 (Pb-212 or 212Pb), are generating interest, but their commercial supply chains are still in the early development phase, and they are currently very difficult to source. These isotopes are also yet to show safety and efficacy in late-stage trials, as opposed to beta emitters, like Cu-67, that have a long history of effectiveness in treating solid tumors.

"The shift away from limited nuclear reactor-based supply, where even today there is an important facility down in Europe due to maintenance issues, is vital in order for radiopharmaceuticals to grow sustainably into the large oncology sector. Copper-67 (Cu-67 or 67Cu) and Targeted Copper Theranostics (TCTs) can now be manufactured and shipped from a single location, a unique feature of Cu-67, due to its ability to be manufactured using electron accelerators.

"By employing TCTs based on Cu-67, Clarity can avoid many of the drawbacks of other therapeutic isotopes, including alpha- and other beta-based therapies. Our TCT therapy programs require only electricity and zinc to make Cu-67, which is now routinely produced in large volumes in the US. The isotope manufacturing is completely modular and scalable, providing significant advantages to increase production in a timely manner. Other advantages of TCTs, such as room temperature manufacturing, reduce the likelihood of batch failures that lead to common supply issues. The fully integrated supply chain of TCTs from production of the isotope to ready-to-use radiopharmaceuticals is unique to Clarity and our platform of therapeutic products under development."

"Given our outstanding clinical trial data to date, we are very excited to secure the supply of Cu-67 and final drug products for the trials with 67Cu-SAR-bisPSMA in prostate cancer as we continue building a sustainable future for radiopharmaceuticals towards our ultimate goal of better treating children and adults with cancer."

The overarching Master Service Agreement and associated Clinical Supply Agreement are effective immediately. The initial supply from NorthStar is expected to occur before the end of calendar year 2024. The Master Services Agreement is for an initial period of 4 years and the Clinical Supply Agreement is for an initial period of 4 years. Cancellation provisions are at industry standard rates.

About SAR Technology
Despite the unique benefits of Cu-67 as a therapeutic isotope for radiopharmaceuticals, historically, the lack of an effective copper chelating technology has limited the clinical development of Cu-67 products and subsequent commercial production of Cu-67. Clarity’s proprietary copper-chelating technology, called "sarcophagine" or SAR Technology, has enabled it to advance the TCT product pipeline into a range of theranostic clinical trials that use copper-64 (Cu-64 or 64Cu) for diagnostic imaging and Cu-67 for therapy. Clarity is currently progressing three key product areas, SAR-bisPSMA, SAR-Bombesin and SARTATE, with three theranostic and four diagnostic clinical trials with a focus on prostate cancer indications.

About SAR-bisPSMA
SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) Technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR Technology prevents copper leakage into the body. SAR-bisPSMA is a TCT that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products. The data outlined in this announcement has not been assessed by health authorities such as the US Food and Drug Administration (FDA). A clinical development program is currently underway to assess the efficacy and safety of these products. There is no guarantee that these products will become commercially available.

On April 3, 2024 Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, reported that it will present a company overview and participate in 1×1 meetings at the 23rd Annual Needham Healthcare Conference on Thursday, April 11, 2024 at 11:00 am ET (Press release, Blacksmith Medicines, APR 3, 2024, View Source [SID1234641734]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Blacksmith Medicines, we are developing a pipeline of novel small molecule medicines targeting metalloenzymes of significant unmet need and high pharma interest, but chemistry limitations have hampered previous efforts that we can solve using our technology platform," said Zachary A. Zimmerman, Ph.D., CEO of Blacksmith. "We look forward to presenting our story at the Needham conference and showcasing the vast number of important metalloenzyme targets, the broad therapeutic application of our technology, and our compelling preclinical data."

About metalloenzymes and the Blacksmith platform

Metalloenzymes utilize a metal ion cofactor in the enzyme active site to perform essential biological functions. This diverse class of targets has historically been difficult to drug due to small molecule chemistry limitations that have plagued the industry. The Blacksmith metalloenzyme platform has solved this problem by leveraging the following:

A large proprietary fragment library of metal-binding pharmacophores (MBPs);
A comprehensive database containing a full characterization of the metalloenzyme genome including functions, metal cofactors, and associations to disease;
A first-of-its-kind metallo-CRISPR library of custom single guide RNAs;
An industry-leading metalloenzyme computational toolkit for docking, modeling and structure-based drug design; and
A robust and blocking intellectual property estate covering bioinorganic, medicinal, and computational chemistry approaches for metalloenzyme-targeted medicines.

On April 3, 2024 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, reported its participation in upcoming investor conferences (Press release, Black Diamond Therapeutics, APR 3, 2024, View Source [SID1234641733]). Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

23rd Annual Needham Virtual Healthcare Conference presentation at 8:00am ET on Wednesday, April 10, 2024
Stifel Virtual Targeted Oncology Forum fireside chat at 10:00am ET on Tuesday, April 16, 2024
Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, in Boston, Mass.
Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.

On April 3, 2024 Bio-Techne Corporation (NASDAQ:TECH) reported it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 5-10, 2024, in San Diego, California (Press release, Bio-Techne, APR 3, 2024, View Source [SID1234641732]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bio-Techne will showcase its solutions at booth #541, featuring our market-leading portfolio of high-grade life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions that are enabling new drug discovery research, accelerating immune cell therapy, and supporting the development of better diagnostic tools. We will also be debuting our Journey into the Tumor Microenvironment video experience in our booth this year. We welcome attendees to explore how different cell types in the tumor microenvironment promote tumor escape through this new interactive platform.

Several scientists from the company will be presenting posters at the conference highlighting our in-house studies in the areas of drug discovery research, automated spatial multiomics, and the development of novel diagnostic tools. These include investigations into validating atypical drug combinations, analyzing the tumor microenvironment by integrated RNA and protein profiling with automated spatial multiomics, developing an exosome/cfDNA methylation blood-based screen for colorectal cancer, and monitoring ESR1 mutations by RT-qPCR in longitudinal studies to predict endocrine therapy resistance.

"We are excited to showcase our portfolio of innovative tools, reagents and workflow solutions that enable the scientific discoveries necessary to advance cancer research," said Kim Kelderman, Bio-Techne’s President and Chief Executive Officer. "Bio-Techne’s portfolio plays a critical role in the development of next-generation cancer therapies, including workflows supporting the emerging class of cell and gene therapies. Our broad presence at AACR (Free AACR Whitepaper) will showcase the many roles Bio-Techne plays in catalyzing advances in science and medicine, and ultimately enabling global populations to live healthier and longer lives."

Bio-Techne Poster Presentations:

Validation of Atypical Drug Combinations Identified from Combination Databases
Sunday, April 7th from 1:30 PM – 5:00 PM
Presenter: Marco Pinheiro, Ph.D.
Poster Section #39, Poster Board #11, Abstract #943

Unveiling the Spatial Dynamics of the Tumor Microenvironment: Integrated RNA and Protein Profiling on the Same Slide through Automated Spatial Multiomics Analysis
Monday, April 8th from 1:30 PM – 5:00 PM
Presenter: Arec Manoukian, Ph.D.
Poster Section #45, Poster Board #20, Abstract #3797

A Kit Targeting Detection of ESR1 Mutations from Circulating Exosomal RNA and Cell-Free DNA Supports Longitudinal Studies into Endocrine Therapy Resistance in a Broadly Accessible RT-qPCR Format
Tuesday, April 9th from 9:00 AM – 12:30 PM
Presenter: Sarah Statt, Ph.D.
Poster Section #26, Poster Board #2, Abstract #4626

Exosome Based Multiomics Combined with cfDNA Methylation Reveals Complementary Signatures in Blood Based Liquid Biopsy that Carry Promise for Minimally Invasive Colorectal Cancer Screening
Wednesday, April 10th from 9:00 AM – 12:30 PM
Presenter: Kyle Manning
Poster Section #51, Poster Board #10, Abstract #LB393

Poster Presentation, In Collaboration

Bladder Cancer Risk Stratification with the Oncuria 10 plex Bead-based Urinalysis Assay Using Three Different Luminex xMAP Instrumentation Platforms
Monday, April 8th from 1:30 PM – 5:00 PM
Presenter: Sunao Tanaka, Ph.D., Postdoctoral Scientist, Cedars-Sinai
Poster Section #44, Poster Board #29, Abstract #3773